HEALTHCARE
Global Gene Therapies Market - Industry Trends and Forecast to 2032
REPORT OVERVIEW
Global Gene Therapies Market, By Type (Gene silencing, Cell replacement, Gene augmentation, Other therapies), Indication (Acute Lymphoblastic Leukemia (ALL), Inherited Retinal Disease, Large B-cell Lymphoma, ADA-SCID, Melanoma (Lesions), Beta-Thalassemia Major/SCD, Head & Neck Squamous Cell Carcinoma, Peripheral Arterial Disease, Spinal Muscular Atrophy (SMA), Others), Gene Type (Antigen, Cytokine, Tumor Suppressor, Suicide, Deficiency, Growth factors, Receptors, Others ), Vector Type (Lentivirus, Adeno-Associated Virus (AAV), Retrovirus & Gamma Retrovirus, Modified Herpes Simplex Virus, Adenovirus, Non-Viral Plasmid Vector, Others), Therapeutic Area (Neurology, Oncology, Hepatology, Other therapeutic areas), Delivery Method (In Vivo and Ex Vivo), Distribution Channel (Hospitals, Clinics, Others), Application (Oncological Disorders, Rare Diseases, Neurological Disorders, Other Diseases), End-user (Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research Institutes), Region (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2032.
Market Insights
The global gene therapies market size is valued to be USD xx million in 2023 and is expected to reach USD xx million by 2032, and it is expected to register a CAGR of xx% over the forecast period 2024-2032.
Gene therapy is the therapeutic introduction of genetic material into a patient's cells to treat or prevent disease. To have a therapeutic impact, this strategy seeks to fix genetic mutations, add therapeutic genes, or alter gene expression. It has the potential for treating diseases when traditional treatments are insufficient, such as some malignancies, genetic abnormalities, and other conditions. The gene therapy market includes the development, manufacture, and commercialization of gene-based medicines. It consists of pharmaceutical corporations, biotechnology companies, and research institutes that work to develop and improve gene therapy products. Clinical trials to assess safety and efficacy, regulatory clearances, and scaling up production for commercial distribution are all key activities in this market. The gene therapy market is positioned for substantial growth and innovation in healthcare as demand increases and technology advance.
The respective global report analyses market trends, consumer behaviour and industry dynamics to guide towards entry into new markets with ease. Also, it assists in tailoring market specific and related products and services to meet the needs, preferences, and expectations of target audience by delving into their psychology. The report also specializes with comprehensive and extensive competitive analysis which offers useful insights into competitor strengths, weaknesses, opportunities, and threats. The respective report offers exclusive insights into the potential impact of disruptive developments and technologies that are expected to completely transform corporate operations. The context includes tailor-made research solutions to create a stronger footprint in their particular industries thereby offering dedicated customized solutions according to the client needs which helps in addressing unique business challenges with more simplified and efficient decision-making solutions.
Market Dynamics
DRIVERS
- High prevalence of genetic disorders.
- Increasing adoption of CRISPR/Cas9 technology.
RESTRAINTS
- High cost of gene therapy treatments.
- Challenges in delivering gene therapies to target cells.
OPPORTUNITIES
- Expansion into rare diseases and oncology segments.
- Development of novel gene editing techniques.
CHALLENGES
- Long-term efficacy and durability of gene therapies.
- Regulatory complexities and approval processes.
SEGMENTATION
- Type
- Gene silencing
- Cell replacement
- Gene augmentation
- Other therapies
- Indication
- Acute Lymphoblastic Leukemia (ALL)
- Inherited Retinal Disease
- Large B-cell Lymphoma
- ADA-SCID, Melanoma (Lesions)
- Beta-Thalassemia Major/SCD
- Head & Neck Squamous Cell Carcinoma
- Peripheral Arterial Disease
- Spinal Muscular Atrophy (SMA)
- Others
- Gene Type
- Antigen
- Cytokine
- Tumor Suppressor
- Suicide
- Deficiency
- Growth factors
- Receptors
- Others
- Vector Type
- Lentivirus
- Adeno-Associated Virus (AAV)
- Retrovirus & Gamma Retrovirus
- Modified Herpes Simplex Virus
- Adenovirus
- Non-Viral Plasmid Vector
- Others
- Therapeutic Area
- Neurology
- Oncology
- Hepatology
- Other therapeutic areas
- Delivery Method
- In Vivo
- Ex Vivo
- Route of Administration
- Intravenous
- Other routes of administration
- Product
- Instruments
- Media
- Sera
- Reagents
- End-user
- Biotechnology Companies
- Pharmaceutical Companies
- Academic Institutes
- Research Institutes
- Application
- Oncological Disorders
- Rare Diseases
- Neurological Disorders
- Other Diseases
- Distribution Channel
- Hospitals
- Clinics
- Others
The respective global report is completely customizable specific to regions (North America, Europe, Asia-Pacific, South America, Middle East and Africa), countries, and segments as per the client requirements.
REGIONAL SEGMENTATION
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- The Netherlands
- Belgium
- Turkey
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Singapore
- Malaysia
- Australia
- Thailand
- Philippines
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Chile
- Colombia
- Rest of South America
- Middle East and Africa
- Kingdom of Saudi Arabia
- South Africa
- U.A.E.
- Egypt
- Rest of Middle East and Africa
KEY MARKET PLAYERS
- American Gene Technologies
- BioMarin
- Bluebird Bio Inc.
- Orchard Therapeutics Limited
- uniQure NV
- BioNTech
- Oxford Biomedica Plc.
- Celgene Corporation
- Shanghai Sunway Biotech Co., Ltd.
- Sibiono GeneTech Co. Ltd.
Table OF CONTENTS
- SECTION 1 - INTRODUCTION
- 1.1 Taxonomy
- 1.2 Market Overview
- 1.3 Currency and Limitations
- 1.3.1 Currency
- 1.3.2 Limitations
- 1.4 Key Competitors
- SECTION 2 - RESEARCH METHODOLOGY
- 2.1 Research Approach
- 2.2 Data Collection and Validation
- 2.2.1 Secondary Research
- 2.2.2 Primary Research
- 2.3 Market Assessment
- 2.3.1 Market Size Estimation
- 2.3.2 Bottom-up Approach
- 2.3.3 Top-down Approach
- 2.3.4 Growth Forecast
- 2.4 Market Study Assumptions
- 2.5 Data Sources
- SECTION 3 - EXECUTIVE SUMMARY
- 3.1 Global Gene Therapies Market, by Type
- 3.2 Global Gene Therapies Market, by Indication
- 3.3 Global Gene Therapies Market, by Gene Type
- 3.4 Global Gene Therapies Market, by Vector Type
- 3.5 Global Gene Therapies Market, by Therapeutic Area
- 3.6 Global Gene Therapies Market, by Delivery Method
- 3.7 Global Gene Therapies Market, by Distribution Channel
- 3.8 Global Gene Therapies Market, by Application
- 3.9 Global Gene Therapies Market, by End-user
- 3.10 Global Gene Therapies Market, by Geography
- 3.11 Market Position Grid
- SECTION 4 - PREMIUM INSIGHTS
- 4.1 Regulatory Framework
- 4.1.1 Standards
- 4.1.2 Regulatory Landscape
- 4.2 Value Chain Analysis
- 4.3 Supply Chain Analysis
- 4.4 COVID-19 Impact
- 4.5 Russia-Ukraine War Impact
- 4.6 PORTER's Five Force Analysis
- 4.7 PESTLE Analysis
- 4.8 SWOT Analysis
- 4.9 Go to Market Strategy
- 4.10 Opportunity Orbit
- 4.11 Multivariate Modelling
- 4.12 Pricing Analysis
- SECTION 5 - MARKET DYNAMICS
- 5.1 Trends
- 5.1.1 Rise in personalized medicine approaches.
- 5.1.2 Advancements in biotechnology and genetic engineering.
- 5.1.3 Trend 3
- 5.2 Drivers
- 5.2.1 High prevalence of genetic disorders.
- 5.2.2 Increasing adoption of CRISPR/Cas9 technology.
- 5.2.3 Driver 3
- 5.2.4 Driver 4
- 5.3 Restraints
- 5.3.1 High cost of gene therapy treatments.
- 5.3.2 Challenges in delivering gene therapies to target cells.
- 5.3.3 Restraint 3
- 5.4 Opportunities
- 5.4.1 Expansion into rare diseases and oncology segments.
- 5.4.2 Development of novel gene editing techniques.
- 5.4.3 Opportunity 3
- 5.4.4 Opportunity 4
- 5.5 Challenges
- 5.5.1 Long-term efficacy and durability of gene therapies.
- 5.5.2 Regulatory complexities and approval processes.
- 5.5.3 Challenge 3
- SECTION 6 - GLOBAL GENE THERAPIES MARKET, BY TYPE
- 6.1 Type Summary
- 6.2 Market Attractive Index
- 6.3 Global Gene Therapies Market, by Type (2019-2032)
- SECTION 7 - GLOBAL GENE THERAPIES MARKET, BY INDICATION
- 7.1 Indication Summary
- 7.2 Market Attractive Index
- 7.3 Global Gene Therapies Market, by Indication (2019-2032)
- SECTION 8 - GLOBAL GENE THERAPIES MARKET, BY GENE TYPE
- 8.1 Gene Type Summary
- 8.2 Market Attractive Index
- 8.3 Global Gene Therapies Market, by Gene Type (2019-2032)
- SECTION 9 - GLOBAL GENE THERAPIES MARKET, BY VECTOR TYPE
- 9.1 Vector Type Summary
- 9.2 Market Attractive Index
- 9.3 Global Gene Therapies Market, by Vector Type (2019-2032)
- SECTION 10 - GLOBAL GENE THERAPIES MARKET, BY THERAPEUTIC AREA
- 10.1 Therapeutic Area Summary
- 10.2 Market Attractive Index
- 10.3 Global Gene Therapies Market, by Therapeutic Area (2019-2032)
- SECTION 11 - GLOBAL GENE THERAPIES MARKET, BY DELIVERY METHOD
- 11.1 Delivery Method Summary
- 11.2 Market Attractive Index
- 11.3 Global Gene Therapies Market, by Delivery Method (2019-2032)
- SECTION 12 - GLOBAL GENE THERAPIES MARKET, BY DISTRIBUTION CHANNEL
- 12.1 Distribution Channel Summary
- 12.2 Market Attractive Index
- 12.3 Global Gene Therapies Market, by Distribution Channel (2019-2032)
- SECTION 13 - GLOBAL GENE THERAPIES MARKET, BY APPLICATION
- 13.1 Application Summary
- 13.2 Market Attractive Index
- 13.3 Global Gene Therapies Market, by Application (2019-2032)
- SECTION 14 - GLOBAL GENE THERAPIES MARKET, BY END-USER
- 14.1 End-user Summary
- 14.2 Market Attractive Index
- 14.3 Global Gene Therapies Market, by End-user (2019-2032)
- SECTION 15 - GLOBAL GENE THERAPIES MARKET, BY GEOGRAPHY
- 15.1 Regional Summary
- 15.2 Market Attractive Index
- 15.3 Global Gene Therapies Market, by Geography (2019-2032)
- SECTION 16 - NORTH AMERICA GENE THERAPIES MARKET
- 16.1 North America Summary
- 16.2 Market Attractive Index
- 16.3 North America Gene Therapies Market, by Type (2019-2032)
- 16.4 North America Gene Therapies Market, by Indication (2019-2032)
- 16.5 North America Gene Therapies Market, by Gene Type (2019-2032)
- 16.6 North America Gene Therapies Market, by Vector Type (2019-2032)
- 16.7 North America Gene Therapies Market, by Therapeutic Area (2019-2032)
- 16.8 North America Gene Therapies Market, by Delivery Method (2019-2032)
- 16.9 North America Gene Therapies Market, by Distribution Channel (2019-2032)
- 16.10 North America Gene Therapies Market, by Application (2019-2032)
- 16.11 North America Gene Therapies Market, by End-user (2019-2032)
- 16.12 North America Gene Therapies Market, by Country (2019-2032)
- 16.12.1 U.S.
- 16.12.2 Canada
- 16.12.3 Mexico
- 16.12.4 Rest of North America
- SECTION 17 - EUROPE GENE THERAPIES MARKET
- 17.1 Europe Summary
- 17.2 Market Attractive Index
- 17.3 Europe Gene Therapies Market, by Type (2019-2032)
- 17.4 Europe Gene Therapies Market, by Indication (2019-2032)
- 17.5 Europe Gene Therapies Market, by Gene Type (2019-2032)
- 17.6 Europe Gene Therapies Market, by Vector Type (2019-2032)
- 17.7 Europe Gene Therapies Market, by Therapeutic Area (2019-2032)
- 17.8 Europe Gene Therapies Market, by Delivery Method (2019-2032)
- 17.9 Europe Gene Therapies Market, by Distribution Channel (2019-2032)
- 17.10 Europe Gene Therapies Market, by Application (2019-2032)
- 17.11 Europe Gene Therapies Market, by End-user (2019-2032)
- 17.12 Europe Gene Therapies Market, by Country (2019-2032)
- 17.12.1 Germany
- 17.12.2 U.K.
- 17.12.3 France
- 17.12.4 Italy
- 17.12.5 Spain
- 17.12.6 Russia
- 17.12.7 The Netherlands
- 17.12.8 Belgium
- 17.12.9 Turkey
- 17.12.10 Rest of Europe
- SECTION 18 - ASIA-PACIFIC GENE THERAPIES MARKET
- 18.1 Asia-Pacific Summary
- 18.2 Market Attractive Index
- 18.3 Asia-Pacific Gene Therapies Market, by Type (2019-2032)
- 18.4 Asia-Pacific Gene Therapies Market, by Indication (2019-2032)
- 18.5 Asia-Pacific Gene Therapies Market, by Gene Type (2019-2032)
- 18.6 Asia-Pacific Gene Therapies Market, by Vector Type (2019-2032)
- 18.7 Asia-Pacific Gene Therapies Market, by Therapeutic Area (2019-2032)
- 18.8 Asia-Pacific Gene Therapies Market, by Delivery Method (2019-2032)
- 18.9 Asia-Pacific Gene Therapies Market, by Distribution Channel (2019-2032)
- 18.10 Asia-Pacific Gene Therapies Market, by Application (2019-2032)
- 18.11 Asia-Pacific Gene Therapies Market, by End-user (2019-2032)
- 18.12 Asia-Pacific Gene Therapies Market, by Country (2019-2032)
- 18.12.1 China
- 18.12.2 India
- 18.12.3 Japan
- 18.12.4 South Korea
- 18.12.5 Singapore
- 18.12.6 Malaysia
- 18.12.7 Australia
- 18.12.8 Thailand
- 18.12.9 Philippines
- 18.12.10 Rest of Asia-Pacific
- SECTION 19 - SOUTH AMERICA GENE THERAPIES MARKET
- 19.1 South America Summary
- 19.2 Market Attractive Index
- 19.3 South America Gene Therapies Market, by Type (2019-2032)
- 19.4 South America Gene Therapies Market, by Indication (2019-2032)
- 19.5 South America Gene Therapies Market, by Gene Type (2019-2032)
- 19.6 South America Gene Therapies Market, by Vector Type (2019-2032)
- 19.7 South America Gene Therapies Market, by Therapeutic Area (2019-2032)
- 19.8 South America Gene Therapies Market, by Delivery Method (2019-2032)
- 19.9 South America Gene Therapies Market, by Distribution Channel (2019-2032)
- 19.10 South America Gene Therapies Market, by Application (2019-2032)
- 19.11 South America Gene Therapies Market, by End-user (2019-2032)
- 19.12 South America Gene Therapies Market, by Country (2019-2032)
- 19.12.1 Brazil
- 19.12.2 Argentina
- 19.12.3 Chile
- 19.12.4 Colombia
- 19.12.5 Rest of South America
- SECTION 20 - MIDDLE EAST AND AFRICA GENE THERAPIES MARKET
- 20.1 Middle East and Africa Summary
- 20.2 Market Attractive Index
- 20.3 Middle East and Africa Gene Therapies Market, by Type (2019-2032)
- 20.4 Middle East and Africa Gene Therapies Market, by Indication (2019-2032)
- 20.5 Middle East and Africa Gene Therapies Market, by Gene Type (2019-2032)
- 20.6 Middle East and Africa Gene Therapies Market, by Vector Type (2019-2032)
- 20.7 Middle East and Africa Gene Therapies Market, by Therapeutic Area (2019-2032)
- 20.8 Middle East and Africa Gene Therapies Market, by Delivery Method (2019-2032)
- 20.9 Middle East and Africa Gene Therapies Market, by Distribution Channel (2019-2032)
- 20.10 Middle East and Africa Gene Therapies Market, by Application (2019-2032)
- 20.11 Middle East and Africa Gene Therapies Market, by End-user (2019-2032)
- 20.12 Middle East and Africa Gene Therapies Market, by Country (2019-2032)
- 20.12.1 Kingdom of Saudi Arabia
- 20.12.2 South Africa
- 20.12.3 U.A.E.
- 20.12.4 Egypt
- 20.12.5 Rest of Middle East and Africa
- SECTION 21 - COMPANY SHARE ANALYSIS
- 21.1 Global Gene Therapies Market, Company Share Analysis
- 21.2 North America Gene Therapies Market, Company Share Analysis
- 21.3 Europe Gene Therapies Market, Company Share Analysis
- 21.4 Asia-Pacific Gene Therapies Market, Company Share Analysis
- SECTION 22 - COMPANY PROFILES
- 22.1 American Gene Technologies
- 22.1.1 Company Snapshot
- 22.1.2 Financial Overview
- 22.1.3 Product Portfolio
- 22.1.4 Recent Developments
- 22.2 BioMarin
- 22.2.1 Company Snapshot
- 22.2.2 Financial Overview
- 22.2.3 Product Portfolio
- 22.2.4 Recent Developments
- 22.3 Bluebird Bio Inc.
- 22.3.1 Company Snapshot
- 22.3.2 Financial Overview
- 22.3.3 Product Portfolio
- 22.3.4 Recent Developments
- 22.4 Orchard Therapeutics Limited
- 22.4.1 Company Snapshot
- 22.4.2 Financial Overview
- 22.4.3 Product Portfolio
- 22.4.4 Recent Developments
- 22.5 UniQure NV
- 22.5.1 Company Snapshot
- 22.5.2 Financial Overview
- 22.5.3 Product Portfolio
- 22.5.4 Recent Developments
- 22.6 BioNTech
- 22.6.1 Company Snapshot
- 22.6.2 Financial Overview
- 22.6.3 Product Portfolio
- 22.6.4 Recent Developments
- 22.7 Oxford Biomedica Plc.
- 22.7.1 Company Snapshot
- 22.7.2 Financial Overview
- 22.7.3 Product Portfolio
- 22.7.4 Recent Developments
- 22.8 Celgene Corporation
- 22.8.1 Company Snapshot
- 22.8.2 Financial Overview
- 22.8.3 Product Portfolio
- 22.8.4 Recent Developments
- 22.9 Shanghai Sunway Biotech Co., Ltd.
- 22.9.1 Company Snapshot
- 22.9.2 Financial Overview
- 22.9.3 Product Portfolio
- 22.9.4 Recent Developments
- 22.10 Sibiono GeneTech Co. Ltd.
- 22.10.1 Company Snapshot
- 22.10.2 Financial Overview
- 22.10.3 Product Portfolio
- 22.10.4 Recent Developments
- SECTION 23 - RELATED REPORTS
- SECTION 24 - DISCLAIMER
RESEARCH METHODOLOGY
The research methodology employed in Uniprism Market Research involves four basic steps namely research and data collection, data pre-processing, modeling and forecasting, quality assurance and output.
RESEARCH AND DATA COLLECTION
A tripod model research technique is followed for research and data collection in which various approaches such as primary research, secondary research, and product mapping are considered.
Primary research basically involves the process of conducting personalized interviews with market related professionals of major market players, investors, distributors, vendors and many more.
The secondary research include data published by government, annual reports, press releases, investor presentations of companies, white papers, certified publications, annual manufacturing limit of the respective industries related to the market, production consumption analysis of certain products respective to the market and many more.
Below mention are few of the sources which we have considered while estimating the market size:
For instance,
- Research articles published on Technium
- Science and MDPI
- Research publications by government approved associations and societies
Product mapping means the process of mapping the list of products that a key player contributes to the market as well as estimating the revenue of those products in order to define the Global Company share analysis of the respective Global Company in global, regional, and country level markets.
DATA PRE-PROCESSING
The term "data pre-processing" refers to the collection of procedures and methods used to clean, modify, and make ready for analysis the raw data gathered during research and data collection. The completion of this phase is necessary to guarantee that the data are reliable, consistent, and appropriate for statistical analysis and other data-driven tasks. The data pre-processing ensures that the information gathered from research and data collection is comparable and expressed in standard units, by the integration of missing data pointers and algorithmic approaches.
MODELING AND FORECASTING
The process of developing mathematical, statistical, or computational representations of real-world occurrences or relationships is known as modelling. These models are intended to replicate and explain market interactions, interdependence, and dynamics. These models are used by Uniprism Market Research to acquire a better knowledge of numerous market characteristics such as customer preferences, pricing elasticity, competition dynamics, and more. Depending on the individual study aims, many types of models are utilized, such as regression models, econometric models, decision tree models, and machine learning models.
Forecasting is the process of predicting future market conditions, trends, and occurrences using past data and models. Forecasting is used by Uniprism Market Research to estimate future sales, demand for products or services, market growth, and other important performance metrics. Forecasting accurately can assist organizations in making educated decisions about resource allocation, pricing, inventory management, and marketing tactics.
We create standardized bottom-up or top-down models that scale by leveraging data science and machine learning technology. All our market models consider the unique market characteristics of each country. Forecasting is based on major market indicators and a combination of traditional methodologies, such as exponential smoothing, time series analysis, regression analysis, and more modern techniques such as machine learning algorithms are all forecasting methodologies. The method chosen is determined on the nature of the data and the specific forecasting aims.
QUALITY ASSURANCE AND OUTPUT
Quality assurance and output involves the process of validation, adjustments, further publications of key market indicators. Extensive plausibility and consistency tests are performed on derived time series to ensure the high degree of quality of our market analysis. This quality assurance procedure also includes rigorous inspection, validation, and editing by an experienced management team to assure the dependability of the published data.